Selected research
Industry Research
Bevacizumab Generics Industry Research Report 2026
Market perspective
The global Bevacizumab Generics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bevacizumab Generics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bevacizumab Generics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Bevacizumab Generics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bevacizumab Generics include Amgen, Amneal Pharmaceuticals, Celltrion Healthcare, Pfizer, Bio-Thera Solutions, Zhejiang Beta Pharma, Jiangsu Hengrui Pharmaceuticals, Qilu Pharma and Shanghai Henlius Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bevacizumab Generics market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bevacizumab Generics Market by Company
Amgen
Amneal Pharmaceuticals
Celltrion Healthcare
Pfizer
Bio-Thera Solutions
Zhejiang Beta Pharma
Jiangsu Hengrui Pharmaceuticals
Qilu Pharma
Shanghai Henlius Biotech
SinoCellTech
Innovent
Chia Tai Tianqing
Bevacizumab Generics Segment by Type
100mg per Vial
400mg per Vial
Bevacizumab Generics Segment by Application
Hospital and Clinic
Retail Pharmacies
Other
Bevacizumab Generics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Generics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Generics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Generics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bevacizumab Generics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bevacizumab Generics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bevacizumab Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100mg per Vial
- 400mg per Vial
Applications
- Hospital and Clinic
- Retail Pharmacies
- Other
Companies covered
- Amgen
- Amneal Pharmaceuticals
- Celltrion Healthcare
- Pfizer
- Bio-Thera Solutions
- Zhejiang Beta Pharma
- Jiangsu Hengrui Pharmaceuticals
- Qilu Pharma
- Shanghai Henlius Biotech
- SinoCellTech
- Innovent
- Chia Tai Tianqing
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bevacizumab Generics Market Size (2021-2032)
- 2.2.2 Global Bevacizumab Generics Sales (2021-2032)
- 2.2.3 Global Bevacizumab Generics Market Average Price (2021-2032)
- 2.3 Bevacizumab Generics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100mg per Vial
- 2.3.3 400mg per Vial
- 2.4 Bevacizumab Generics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Retail Pharmacies
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bevacizumab Generics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bevacizumab Generics Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Bevacizumab Generics Revenue of Manufacturers (2021-2026)
- 3.4 Global Bevacizumab Generics Average Price by Manufacturers (2021-2026)
- 3.5 Global Bevacizumab Generics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bevacizumab Generics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bevacizumab Generics, Product Type & Application
- 3.8 Global Manufacturers of Bevacizumab Generics, Established Date
- 3.9 Global Bevacizumab Generics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Amgen
- 4.1.1 Amgen Company Information
- 4.1.2 Amgen Business Overview
- 4.1.3 Amgen Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Amgen Bevacizumab Generics Product Portfolio
- 4.1.5 Amgen Recent Developments
- 4.2 Amneal Pharmaceuticals
- 4.2.1 Amneal Pharmaceuticals Company Information
- 4.2.2 Amneal Pharmaceuticals Business Overview
- 4.2.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolio
- 4.2.5 Amneal Pharmaceuticals Recent Developments
- 4.3 Celltrion Healthcare
- 4.3.1 Celltrion Healthcare Company Information
- 4.3.2 Celltrion Healthcare Business Overview
- 4.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Celltrion Healthcare Bevacizumab Generics Product Portfolio
- 4.3.5 Celltrion Healthcare Recent Developments
- 4.4 Pfizer
- 4.4.1 Pfizer Company Information
- 4.4.2 Pfizer Business Overview
- 4.4.3 Pfizer Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Pfizer Bevacizumab Generics Product Portfolio
- 4.4.5 Pfizer Recent Developments
- 4.5 Bio-Thera Solutions
- 4.5.1 Bio-Thera Solutions Company Information
- 4.5.2 Bio-Thera Solutions Business Overview
- 4.5.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Bio-Thera Solutions Bevacizumab Generics Product Portfolio
- 4.5.5 Bio-Thera Solutions Recent Developments
- 4.6 Zhejiang Beta Pharma
- 4.6.1 Zhejiang Beta Pharma Company Information
- 4.6.2 Zhejiang Beta Pharma Business Overview
- 4.6.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolio
- 4.6.5 Zhejiang Beta Pharma Recent Developments
- 4.7 Jiangsu Hengrui Pharmaceuticals
- 4.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 4.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 4.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolio
- 4.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 4.8 Qilu Pharma
- 4.8.1 Qilu Pharma Company Information
- 4.8.2 Qilu Pharma Business Overview
- 4.8.3 Qilu Pharma Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Qilu Pharma Bevacizumab Generics Product Portfolio
- 4.8.5 Qilu Pharma Recent Developments
- 4.9 Shanghai Henlius Biotech
- 4.9.1 Shanghai Henlius Biotech Company Information
- 4.9.2 Shanghai Henlius Biotech Business Overview
- 4.9.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolio
- 4.9.5 Shanghai Henlius Biotech Recent Developments
- 4.10 SinoCellTech
- 4.10.1 SinoCellTech Company Information
- 4.10.2 SinoCellTech Business Overview
- 4.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 SinoCellTech Bevacizumab Generics Product Portfolio
- 4.10.5 SinoCellTech Recent Developments
- 4.11 Innovent
- 4.11.1 Innovent Company Information
- 4.11.2 Innovent Business Overview
- 4.11.3 Innovent Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Innovent Bevacizumab Generics Product Portfolio
- 4.11.5 Innovent Recent Developments
- 4.12 Chia Tai Tianqing
- 4.12.1 Chia Tai Tianqing Company Information
- 4.12.2 Chia Tai Tianqing Business Overview
- 4.12.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Chia Tai Tianqing Bevacizumab Generics Product Portfolio
- 4.12.5 Chia Tai Tianqing Recent Developments
5 Global Bevacizumab Generics Market Scenario by Region
- 5.1 Global Bevacizumab Generics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bevacizumab Generics Sales by Region: 2021-2032
- 5.2.1 Global Bevacizumab Generics Sales by Region: 2021-2026
- 5.2.2 Global Bevacizumab Generics Sales by Region: 2027-2032
- 5.3 Global Bevacizumab Generics Revenue by Region: 2021-2032
- 5.3.1 Global Bevacizumab Generics Revenue by Region: 2021-2026
- 5.3.2 Global Bevacizumab Generics Revenue by Region: 2027-2032
- 5.4 North America Bevacizumab Generics Market Facts & Figures by Country
- 5.4.1 North America Bevacizumab Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bevacizumab Generics Sales by Country (2021-2032)
- 5.4.3 North America Bevacizumab Generics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Bevacizumab Generics Market Facts & Figures by Country
- 5.5.1 Europe Bevacizumab Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bevacizumab Generics Sales by Country (2021-2032)
- 5.5.3 Europe Bevacizumab Generics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Bevacizumab Generics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bevacizumab Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bevacizumab Generics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bevacizumab Generics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bevacizumab Generics Market Facts & Figures by Country
- 5.7.1 South America Bevacizumab Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bevacizumab Generics Sales by Country (2021-2032)
- 5.7.3 South America Bevacizumab Generics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Bevacizumab Generics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bevacizumab Generics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bevacizumab Generics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bevacizumab Generics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Bevacizumab Generics Sales by Type (2021-2032)
- 6.1.1 Global Bevacizumab Generics Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Bevacizumab Generics Sales Market Share by Type (2021-2032)
- 6.2 Global Bevacizumab Generics Revenue by Type (2021-2032)
- 6.2.1 Global Bevacizumab Generics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bevacizumab Generics Revenue Market Share by Type (2021-2032)
- 6.3 Global Bevacizumab Generics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bevacizumab Generics Sales by Application (2021-2032)
- 7.1.1 Global Bevacizumab Generics Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Bevacizumab Generics Sales Market Share by Application (2021-2032)
- 7.2 Global Bevacizumab Generics Revenue by Application (2021-2032)
- 7.2.1 Global Bevacizumab Generics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bevacizumab Generics Revenue Market Share by Application (2021-2032)
- 7.3 Global Bevacizumab Generics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bevacizumab Generics Value Chain Analysis
- 8.1.1 Bevacizumab Generics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bevacizumab Generics Production Mode & Process
- 8.2 Bevacizumab Generics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bevacizumab Generics Distributors
- 8.2.3 Bevacizumab Generics Customers
9 Global Bevacizumab Generics Analyzing Market Dynamics
- 9.1 Bevacizumab Generics Industry Trends
- 9.2 Bevacizumab Generics Industry Drivers
- 9.3 Bevacizumab Generics Industry Opportunities and Challenges
- 9.4 Bevacizumab Generics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst